Gaithersburg, Maryland-based Vtesse, a developer of drugs for patients suffering from “underserved” diseases, has raised $17 million in Series A funding. The investors included Alexandria Venture Investments, Bay City Capital LLC, Lundbeckfond Ventures, New Enterprise Associates and Pfizer Venture Investments.
Source: Press Release